Tumor panel screens with primary cell suspensions prepared from patient-derived xenografts (PDX Models) and cell line-derived xenografts (CDX Models) can be used to assess the efficacy of drug candidate compounds to inhibit anchorage-independent growth of single cells and ex vivo formation of tumor organoids in single agent of matrix combination layouts. These screens can also investigate if anti-tumor activity is selective for different histologies or dependent on molecular markers.

These panel screens represent time- and cost-effective tools in the earliest stages of research to characterize developmental compounds for anti-cancer efficacy and selectivity to determine candidate tumor models for subsequent in vivo studies, or to support biomarker identification via bioinformatics approaches. Download our data, and contact us to discuss your project or with any questions you may have at 1.877.CRIVER.1 (1.877.274.8371).